OpenLegislation

Division 3.4.2.1.2.3 F1

United Kingdom

Original text. Later amendments are not shown.

The evidence referred to above could be:

  1. (a)

    clinical history and data from appropriate lung function tests related to exposure to the substance, confirmed by other supportive evidence which may include:

    1. (i)

      in vivo immunological test (e.g. skin prick test);

    2. (ii)

      in vitro immunological test (e.g. serological analysis);

    3. (iii)

      studies that indicate other specific hypersensitivity reactions where immunological mechanisms of action have not been proven, e.g. repeated low-level irritation, pharmacologically mediated effects;

    4. (iv)

      a chemical structure related to substances known to cause respiratory hypersensitivity;

  2. (b)

    data from one or more positive bronchial challenge tests with the substance conducted according to accepted guidelines for the determination of a specific hypersensitivity reaction.

Annotations

Textual amendments

F1

Substituted by Commission Regulation (EU) No 286/2011 of 10 March 2011 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance).